MAYO CLINIC
Mayo Medical Laboratories

# Laboratory Service Report 1-800-533-1710

| Patient Name | Patient ID | Age | Gender | Order # |
|---|---|---|---|---|
| TESTINGRNV,GTPMT NEG | SA00065671 | 39 | M | SA00065671 |
| **Ordering Phys**<br>CLIENT,CLIENT | | | | **DOB**<br>01/01/1975 |
| **Client Order #**<br>SA00065671 | **Account Information** | | | **Report Notes** |
| **Collected**<br>02/18/2014 06:00 | C7028846-DLMP Rochester<br>SDSC 2 - Client Support<br>Rochester, MN 55901 | | | |
| **Printed**<br>03/10/2014 13:51 | | | | |

| Test | Flag | Results | Unit | Reference Value | Perform Site* |
|---|---|---|---|---|---|

**TPMT Genotype, B**
**RECEIVED:** 02/19/2014 08:28 **REPORTED:** 02/19/2014 08:58

TPMT Genotype Result 1/1 MCR

TPMT *2, *3A, *3B and *3C were not detected. This individual most likely has a TPMT *1/*1 genotype.

TPMT Interpretation MCR

This patient most likely has extensive (normal) TPMT activity.
Dosing guidance for thiopurines can be found at: CPIC guidelines http://www.pharmgkb.org/gene/PA356.

Since some adverse reactions to thiopurine drugs, including myelosuppression, are not explained by TPMT (Genbank # NM_000367.2), regular monitoring of complete blood count (CBC) and liver function tests is still essential.

This test detects TPMT*2, *3A, *3B, and *3C. If these alleles are not detected, the patient most likely has the *1/*1 genotype. There is a small residual risk that other rare alleles may be present which are not detected by this assay and which might affect the patients response to thiopurine drugs. This genotyping method will not distinguish between a heterozygous *3A and the very rare *3B/*3C, which is associated with poor (deficient) enzyme activity. Evaluation of enzyme activity is necessary to definitively identify this rare genotype (Order Mayo Test ID TPMT, secondary ID 80291, Published name: Thiopurine Methyltransferase (TPMT), Erythrocyte using the specimen requirements for this test).

Inhibitors:
Co-prescription of allopurinol might inhibit TPMT activity. Drugs that have been shown to inhibit TPMT activity include: naproxen, ibuprofen, ketoprofen, furosemide, sulfasalazine, mesalamine, olsalazine, mefenamic acid, thiazide diuretics, and benzoic acid inhibitors.

If the patient has had an allogeneic blood or marrow transplant or a recent (i.e. less than 6 weeks from time of sample collection) heterologous blood transfusion these results may be inaccurate due to the presence of donor DNA.
Laboratory developed test.

Reviewed By See Below MCR

Result:Linnea M. Baudhuin, Ph.D.

***Performing Site Legend on Last Page of Report***

MAYO CLINIC
Mayo Medical Laboratories

# Laboratory Service Report

**1-800-533-1710**

| Patient Name | Patient ID | Age | Gender | Order # |
|---|---|---|---|---|
| TESTINGRNV,GTPMT NEG | SA00065671 | 39 | M | SA00065671 |
| **Ordering Phys**<br>CLIENT,CLIENT | | | | **DOB**<br>01/01/1975 |
| **Client Order #**<br>SA00065671 | **Account Information** | | | **Report Notes** |
| **Collected**<br>02/18/2014 06:00 | C7028846-DLMP Rochester<br>SDSC 2 - Client Support<br>Rochester, MN 55901 | | | |
| **Printed**<br>03/10/2014 13:51 | | | | |

| Test | Flag | Results | Unit | Reference Value | Perform Site* |
|---|---|---|---|---|---|

>> Accession SA00065671 - Continued From Previous Page <<
>> Do Not Discard <<

* Performing Site:

| | | |
|---|---|---|
| MCR | Mayo Clinic Laboratories - Rochester Main Campus<br>200 First St SW Rochester, MN 55905 | Lab Director: |



* Report times for Mayo performed tests are CST/CDT